Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic

The FDA granted argenx Priority Review status for the company’s Biologics License Application for SC efgartigimod for generalized myasthenia gravis (gMG).

The drug is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s Enhanze drug delivery system. Enhanze helps deliver biologics subcutaneously that are usually administered via intravenous infusion.